Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

The existence of cognitive plateaus in Alzheimer's disease

Authors
Bozoki, Andrea C.An, HyongginBozoki, Eva S.Little, Roderick J.
Issue Date
11월-2009
Publisher
ELSEVIER SCIENCE INC
Keywords
Alzheimer' s disease; Cognition; Dementia; Neuropsychology
Citation
ALZHEIMERS & DEMENTIA, v.5, no.6, pp.470 - 478
Indexed
SCIE
SCOPUS
Journal Title
ALZHEIMERS & DEMENTIA
Volume
5
Number
6
Start Page
470
End Page
478
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/118982
DOI
10.1016/j.jalz.2009.05.669
ISSN
1552-5260
Abstract
Background: The objective of this study was to evaluate the existence of cognitive plateaus in some individuals during the course of Alzheimer's disease (AD). Methods: Data came from the historical patient group collected via the Consortium to Establish a Registry for Alzheimer's Disease (CERAD, Duke University, 1988-1996). Data reduction was performed by using principal components analysis to derive a single cognitive measure (F1), followed by application of a novel plateau-searching algorithm to individual patient data, looking for stable periods of 3 years or longer. To evaluate the time dependence of F1, we fitted a linear mixed model to the group and to individual data points. Results: Twenty-two percent of AD subjects (54/243) and 98% of healthy control subjects (253/258) exhibited a plateau. Within the AD plateau group, the most common pattern was a single plateau (mean, 3.6 years; range, 3 to 7 years) that extended for the entire measurement period (28/54 subjects). Briefer plateau durations were seen at the beginning or end of the measurement period. Initial cognitive function (F1) was slightly higher in the plateau group, which was also slightly older and less well-educated. Men and women were equally represented. Conclusions: In a patient sample predating the widespread use of cholinesterase inhibitors, we found that approximately one fifth of individuals with AD demonstrated periods of prolonged cognitive stability. This significant interindividual variability must be considered when providing prognostic information to families and when assessing individual patient responses to pharmacotherapy. We advise caution when assessing results of potentially disease-modifying agents at the individual patient level. (C) 2009 The Alzheimer's Association. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE